You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameBopindolol
Accession NumberDB08807
TypeSmall Molecule
GroupsApproved
DescriptionBopindolol (INN) is a beta blocker. It is an ester which acts as a prodrug for "pindolol":http://drugbank.ca/drugs/DB00960.
Structure
Thumb
Synonyms
Sandonorm
External Identifiers Not Available
Approved Prescription ProductsNot Available
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
SandonormNot Available
Brand mixturesNot Available
SaltsNot Available
Categories
UNIIKT304VZO57
CAS number62658-63-3
WeightAverage: 380.48
Monoisotopic: 380.209992772
Chemical FormulaC23H28N2O3
InChI KeyInChIKey=UUOJIACWOAYWEZ-UHFFFAOYSA-N
InChI
InChI=1S/C23H28N2O3/c1-16-13-19-20(25-16)11-8-12-21(19)27-15-18(14-24-23(2,3)4)28-22(26)17-9-6-5-7-10-17/h5-13,18,24-25H,14-15H2,1-4H3
IUPAC Name
1-(tert-butylamino)-3-[(2-methyl-1H-indol-4-yl)oxy]propan-2-yl benzoate
SMILES
CC1=CC2=C(N1)C=CC=C2OCC(CNC(C)(C)C)OC(=O)C1=CC=CC=C1
Taxonomy
ClassificationNot classified
Pharmacology
IndicationFor the management of hypertension, edema, ventricular tachycardias, and atrial fibrillation.
PharmacodynamicsBopindolol is a prodrug of pindolol. Pindolol is a non-selective beta-adrenergic antagonist (beta-blocker) which possesses intrinsic sympathomimetic activity (ISA) in therapeutic dosage ranges but does not possess quinidine-like membrane stabilizing activity. Pindolol impairs AV node conduction and decreases sinus rate and may also increase plasma triglycerides and decrease HDL-cholesterol levels. Pindolol is nonpolar and hydrophobic, with low to moderate lipid solubility. Pindolol has little to no intrinsic sympathomimetic activity and, unlike some other beta-adrenergic blocking agents, pindolol has little direct myocardial depressant activity and does not have an anesthetic-like membrane-stabilizing action.
Mechanism of actionBopindolol (as pindolol) non-selectively blocks beta-1 adrenergic receptors mainly in the heart, inhibiting the effects of epinephrine and norepinephrine resulting in a decrease in heart rate and blood pressure. By binding beta-2 receptors in the juxtaglomerular apparatus, Pindolol inhibits the production of renin, thereby inhibiting angiotensin II and aldosterone production and therefore inhibits the vasoconstriction and water retention due to angiotensin II and aldosterone, respectively.
Related Articles
AbsorptionNot Available
Volume of distributionNot Available
Protein bindingNot Available
MetabolismNot Available
Route of eliminationNot Available
Half lifeNot Available
ClearanceNot Available
ToxicityNot Available
Affected organisms
  • Humans and other mammals
Pathways
PathwayCategorySMPDB ID
Bopindolol Action PathwayDrug actionSMP00657
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+1.0
Blood Brain Barrier+0.7031
Caco-2 permeable+0.5503
P-glycoprotein substrateSubstrate0.6988
P-glycoprotein inhibitor IInhibitor0.558
P-glycoprotein inhibitor IINon-inhibitor0.598
Renal organic cation transporterNon-inhibitor0.7224
CYP450 2C9 substrateNon-substrate0.8035
CYP450 2D6 substrateSubstrate0.5082
CYP450 3A4 substrateNon-substrate0.5144
CYP450 1A2 substrateInhibitor0.7481
CYP450 2C9 inhibitorNon-inhibitor0.6637
CYP450 2D6 inhibitorNon-inhibitor0.6918
CYP450 2C19 inhibitorInhibitor0.5217
CYP450 3A4 inhibitorNon-inhibitor0.5458
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.9049
Ames testNon AMES toxic0.8135
CarcinogenicityNon-carcinogens0.9013
BiodegradationNot ready biodegradable1.0
Rat acute toxicity2.7343 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9897
hERG inhibition (predictor II)Non-inhibitor0.63
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
PackagersNot Available
Dosage formsNot Available
PricesNot Available
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point152–153 [malonate salt]MSDS
water solubility3.3 mg/ml (malonate salt)Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.0016 mg/mLALOGPS
logP4.45ALOGPS
logP4.67ChemAxon
logS-5.4ALOGPS
pKa (Strongest Acidic)16.8ChemAxon
pKa (Strongest Basic)9.29ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area63.35 Å2ChemAxon
Rotatable Bond Count9ChemAxon
Refractivity111.07 m3·mol-1ChemAxon
Polarizability43.08 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
References
Synthesis ReferenceNot Available
General ReferencesNot Available
External Links
ATC CodesC07CA17C07AA17
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelNot Available
MSDSDownload (125 KB)
Interactions
Drug Interactions
Drug
1,10-Phenanthroline1,10-Phenanthroline may increase the bradycardic activities of Bopindolol.
4-Methoxyamphetamine4-Methoxyamphetamine may increase the atrioventricular blocking (AV block) activities of Bopindolol.
AceclofenacAceclofenac may decrease the antihypertensive activities of Bopindolol.
AcepromazineAcepromazine may increase the hypotensive activities of Bopindolol.
AcetohexamideBopindolol may increase the hypoglycemic activities of Acetohexamide.
AcetylcholineThe risk or severity of adverse effects can be increased when Bopindolol is combined with Acetylcholine.
AcetyldigitoxinBopindolol may increase the bradycardic activities of Acetyldigitoxin.
Acetylsalicylic acidAcetylsalicylic acid may decrease the antihypertensive activities of Bopindolol.
AdapaleneAdapalene may decrease the antihypertensive activities of Bopindolol.
AgmatineAgmatine may increase the atrioventricular blocking (AV block) activities of Bopindolol.
AlfuzosinBopindolol may increase the orthostatic hypotensive activities of Alfuzosin.
AlimemazineAlimemazine may increase the hypotensive activities of Bopindolol.
AmbenoniumAmbenonium may increase the bradycardic activities of Bopindolol.
AminophyllineBopindolol may decrease the bronchodilatory activities of Aminophylline.
AmiodaroneAmiodarone may increase the bradycardic activities of Bopindolol.
AmobarbitalThe serum concentration of Bopindolol can be decreased when it is combined with Amobarbital.
AmodiaquineThe metabolism of Bopindolol can be decreased when combined with Amodiaquine.
AmoxapineThe serum concentration of Bopindolol can be increased when it is combined with Amoxapine.
AntipyrineAntipyrine may decrease the antihypertensive activities of Bopindolol.
ApomorphineApomorphine may increase the atrioventricular blocking (AV block) activities of Bopindolol.
ApraclonidineApraclonidine may increase the atrioventricular blocking (AV block) activities of Bopindolol.
ApremilastApremilast may decrease the antihypertensive activities of Bopindolol.
ArbutamineBopindolol may decrease the bronchodilatory activities of Arbutamine.
ArecolineThe risk or severity of adverse effects can be increased when Bopindolol is combined with Arecoline.
ArformoterolBopindolol may decrease the bronchodilatory activities of Arformoterol.
AzapropazoneAzapropazone may decrease the antihypertensive activities of Bopindolol.
AzelastineAzelastine may decrease the antihypertensive activities of Bopindolol.
BalsalazideBalsalazide may decrease the antihypertensive activities of Bopindolol.
BambuterolBopindolol may decrease the bronchodilatory activities of Bambuterol.
BarbitalThe serum concentration of Bopindolol can be decreased when it is combined with Barbital.
BenoxaprofenBenoxaprofen may decrease the antihypertensive activities of Bopindolol.
BenzphetamineBenzphetamine may increase the atrioventricular blocking (AV block) activities of Bopindolol.
BethanecholThe risk or severity of adverse effects can be increased when Bopindolol is combined with Bethanechol.
BethanidineBethanidine may increase the atrioventricular blocking (AV block) activities of Bopindolol.
BrimonidineBrimonidine may increase the atrioventricular blocking (AV block) activities of Bopindolol.
BromfenacBromfenac may decrease the antihypertensive activities of Bopindolol.
BromocriptineBopindolol may increase the vasoconstricting activities of Bromocriptine.
BromocriptineBromocriptine may increase the atrioventricular blocking (AV block) activities of Bopindolol.
BupivacaineThe serum concentration of Bupivacaine can be increased when it is combined with Bopindolol.
CabergolineBopindolol may increase the vasoconstricting activities of Cabergoline.
CarbacholThe risk or severity of adverse effects can be increased when Bopindolol is combined with Carbachol.
CarprofenCarprofen may decrease the antihypertensive activities of Bopindolol.
CarvedilolBopindolol may increase the orthostatic hypotensive activities of Carvedilol.
CastanospermineCastanospermine may decrease the antihypertensive activities of Bopindolol.
CelecoxibCelecoxib may decrease the antihypertensive activities of Bopindolol.
CeliprololBopindolol may decrease the bronchodilatory activities of Celiprolol.
CevimelineThe risk or severity of adverse effects can be increased when Bopindolol is combined with Cevimeline.
ChloroquineChloroquine may decrease the antihypertensive activities of Bopindolol.
ChlorpromazineChlorpromazine may increase the hypotensive activities of Bopindolol.
ChlorpropamideBopindolol may increase the hypoglycemic activities of Chlorpropamide.
ClenbuterolBopindolol may decrease the bronchodilatory activities of Clenbuterol.
ClomipramineThe serum concentration of Bopindolol can be increased when it is combined with Clomipramine.
ClonidineClonidine may increase the atrioventricular blocking (AV block) activities of Bopindolol.
ClonixinClonixin may decrease the antihypertensive activities of Bopindolol.
CoumaphosCoumaphos may increase the bradycardic activities of Bopindolol.
D-LimoneneD-Limonene may decrease the antihypertensive activities of Bopindolol.
DapoxetineThe serum concentration of Bopindolol can be increased when it is combined with Dapoxetine.
DecamethoniumDecamethonium may increase the bradycardic activities of Bopindolol.
DemecariumDemecarium may increase the bradycardic activities of Bopindolol.
DeslanosideBopindolol may increase the bradycardic activities of Deslanoside.
DexmedetomidineDexmedetomidine may increase the atrioventricular blocking (AV block) activities of Bopindolol.
DichlorvosDichlorvos may increase the bradycardic activities of Bopindolol.
DiclofenacDiclofenac may decrease the antihypertensive activities of Bopindolol.
DiflunisalDiflunisal may decrease the antihypertensive activities of Bopindolol.
DigitoxinBopindolol may increase the bradycardic activities of Digitoxin.
DigoxinBopindolol may increase the bradycardic activities of Digoxin.
DihydroergotamineBopindolol may increase the vasoconstricting activities of Dihydroergotamine.
DihydroergotamineDihydroergotamine may increase the atrioventricular blocking (AV block) activities of Bopindolol.
DipivefrinDipivefrin may increase the atrioventricular blocking (AV block) activities of Bopindolol.
DipivefrinBopindolol may decrease the bronchodilatory activities of Dipivefrin.
DipyridamoleDipyridamole may increase the bradycardic activities of Bopindolol.
DisopyramideDisopyramide may increase the bradycardic activities of Bopindolol.
DobutamineBopindolol may decrease the bronchodilatory activities of Dobutamine.
DonepezilDonepezil may increase the bradycardic activities of Bopindolol.
DoxazosinBopindolol may increase the orthostatic hypotensive activities of Doxazosin.
DronedaroneDronedarone may increase the bradycardic activities of Bopindolol.
DroxicamDroxicam may decrease the antihypertensive activities of Bopindolol.
DroxidopaDroxidopa may increase the atrioventricular blocking (AV block) activities of Bopindolol.
DroxidopaBopindolol may decrease the bronchodilatory activities of Droxidopa.
DyphyllineBopindolol may decrease the bronchodilatory activities of Dyphylline.
EchothiophateEchothiophate may increase the bradycardic activities of Bopindolol.
EdrophoniumEdrophonium may increase the bradycardic activities of Bopindolol.
EphedraEphedra may increase the atrioventricular blocking (AV block) activities of Bopindolol.
EphedraBopindolol may decrease the bronchodilatory activities of Ephedra.
EPIBATIDINEThe risk or severity of adverse effects can be increased when Bopindolol is combined with EPIBATIDINE.
EpinephrineEpinephrine may increase the atrioventricular blocking (AV block) activities of Bopindolol.
EpinephrineBopindolol may decrease the bronchodilatory activities of Epinephrine.
EpirizoleEpirizole may decrease the antihypertensive activities of Bopindolol.
Ergoloid mesylateBopindolol may increase the vasoconstricting activities of Ergoloid mesylate.
ErgonovineBopindolol may increase the vasoconstricting activities of Ergonovine.
ErgotamineBopindolol may increase the vasoconstricting activities of Ergotamine.
ErgotamineErgotamine may increase the atrioventricular blocking (AV block) activities of Bopindolol.
EtanerceptEtanercept may decrease the antihypertensive activities of Bopindolol.
EtodolacEtodolac may decrease the antihypertensive activities of Bopindolol.
EtofenamateEtofenamate may decrease the antihypertensive activities of Bopindolol.
EtomidateEtomidate may increase the atrioventricular blocking (AV block) activities of Bopindolol.
EtoperidoneThe serum concentration of Bopindolol can be increased when it is combined with Etoperidone.
EtoricoxibEtoricoxib may decrease the antihypertensive activities of Bopindolol.
Evening primrose oilEvening primrose oil may decrease the antihypertensive activities of Bopindolol.
exisulindexisulind may decrease the antihypertensive activities of Bopindolol.
FenbufenFenbufen may decrease the antihypertensive activities of Bopindolol.
FenfluramineThe serum concentration of Bopindolol can be increased when it is combined with Fenfluramine.
FenoprofenFenoprofen may decrease the antihypertensive activities of Bopindolol.
FenoterolBopindolol may decrease the bronchodilatory activities of Fenoterol.
FenthionFenthion may increase the bradycardic activities of Bopindolol.
FingolimodBopindolol may increase the bradycardic activities of Fingolimod.
FloctafenineThe risk or severity of adverse effects can be increased when Floctafenine is combined with Bopindolol.
FlunixinFlunixin may decrease the antihypertensive activities of Bopindolol.
FluoxetineThe serum concentration of Bopindolol can be increased when it is combined with Fluoxetine.
FluphenazineFluphenazine may increase the hypotensive activities of Bopindolol.
FlurbiprofenFlurbiprofen may decrease the antihypertensive activities of Bopindolol.
FormoterolBopindolol may decrease the bronchodilatory activities of Formoterol.
GalantamineGalantamine may increase the bradycardic activities of Bopindolol.
Gallamine TriethiodideGallamine Triethiodide may increase the bradycardic activities of Bopindolol.
Ginkgo bilobaGinkgo biloba may increase the bradycardic activities of Bopindolol.
GlibornurideBopindolol may increase the hypoglycemic activities of Glibornuride.
GliclazideBopindolol may increase the hypoglycemic activities of Gliclazide.
GlimepirideBopindolol may increase the hypoglycemic activities of Glimepiride.
GlipizideBopindolol may increase the hypoglycemic activities of Glipizide.
GliquidoneBopindolol may increase the hypoglycemic activities of Gliquidone.
GlisoxepideBopindolol may increase the hypoglycemic activities of Glisoxepide.
GlyburideBopindolol may increase the hypoglycemic activities of Glyburide.
GTS-21The risk or severity of adverse effects can be increased when Bopindolol is combined with GTS-21.
GuanabenzGuanabenz may increase the atrioventricular blocking (AV block) activities of Bopindolol.
GuanfacineGuanfacine may increase the atrioventricular blocking (AV block) activities of Bopindolol.
HexobarbitalThe serum concentration of Bopindolol can be decreased when it is combined with Hexobarbital.
HMPL-004HMPL-004 may decrease the antihypertensive activities of Bopindolol.
Huperzine AHuperzine A may increase the bradycardic activities of Bopindolol.
HydroxychloroquineThe metabolism of Bopindolol can be decreased when combined with Hydroxychloroquine.
IbuprofenIbuprofen may decrease the antihypertensive activities of Bopindolol.
IbuproxamIbuproxam may decrease the antihypertensive activities of Bopindolol.
IcatibantIcatibant may decrease the antihypertensive activities of Bopindolol.
IndacaterolBopindolol may decrease the bronchodilatory activities of Indacaterol.
IndalpineThe serum concentration of Bopindolol can be increased when it is combined with Indalpine.
IndomethacinIndomethacin may decrease the antihypertensive activities of Bopindolol.
IndoprofenIndoprofen may decrease the antihypertensive activities of Bopindolol.
IndoraminBopindolol may increase the orthostatic hypotensive activities of Indoramin.
Insulin PorkBopindolol may increase the hypoglycemic activities of Insulin Pork.
IsoetarineBopindolol may decrease the bronchodilatory activities of Isoetarine.
IsoflurophateIsoflurophate may increase the bradycardic activities of Bopindolol.
IsoprenalineBopindolol may decrease the bronchodilatory activities of Isoprenaline.
IsoxicamIsoxicam may decrease the antihypertensive activities of Bopindolol.
KebuzoneKebuzone may decrease the antihypertensive activities of Bopindolol.
KetoprofenKetoprofen may decrease the antihypertensive activities of Bopindolol.
KetorolacKetorolac may decrease the antihypertensive activities of Bopindolol.
LabetalolBopindolol may increase the orthostatic hypotensive activities of Labetalol.
LeflunomideLeflunomide may decrease the antihypertensive activities of Bopindolol.
LevomilnacipranThe serum concentration of Bopindolol can be increased when it is combined with Levomilnacipran.
LidocaineThe serum concentration of Lidocaine can be increased when it is combined with Bopindolol.
LobelineThe risk or severity of adverse effects can be increased when Bopindolol is combined with Lobeline.
LofexidineLofexidine may increase the atrioventricular blocking (AV block) activities of Bopindolol.
LornoxicamLornoxicam may decrease the antihypertensive activities of Bopindolol.
LoxoprofenLoxoprofen may decrease the antihypertensive activities of Bopindolol.
Lu AA21004The serum concentration of Bopindolol can be increased when it is combined with Lu AA21004.
LumiracoxibLumiracoxib may decrease the antihypertensive activities of Bopindolol.
Magnesium salicylateMagnesium salicylate may decrease the antihypertensive activities of Bopindolol.
MalathionMalathion may increase the bradycardic activities of Bopindolol.
MasoprocolMasoprocol may decrease the antihypertensive activities of Bopindolol.
Meclofenamic acidMeclofenamic acid may decrease the antihypertensive activities of Bopindolol.
Mefenamic acidMefenamic acid may decrease the antihypertensive activities of Bopindolol.
MefloquineMefloquine may increase the bradycardic activities of Bopindolol.
MeloxicamMeloxicam may decrease the antihypertensive activities of Bopindolol.
MemantineMemantine may increase the bradycardic activities of Bopindolol.
MepivacaineThe serum concentration of Mepivacaine can be increased when it is combined with Bopindolol.
MesalazineMesalazine may decrease the antihypertensive activities of Bopindolol.
MesoridazineMesoridazine may increase the hypotensive activities of Bopindolol.
MetamizoleMetamizole may decrease the antihypertensive activities of Bopindolol.
MethacholineThe risk or severity of adverse effects can be increased when Bopindolol is combined with Methacholine.
MethamphetamineMethamphetamine may increase the atrioventricular blocking (AV block) activities of Bopindolol.
MethohexitalThe serum concentration of Bopindolol can be decreased when it is combined with Methohexital.
MethotrimeprazineMethotrimeprazine may increase the hypotensive activities of Bopindolol.
Methylene blueMethylene blue may increase the hypotensive activities of Bopindolol.
MethylphenobarbitalThe serum concentration of Bopindolol can be decreased when it is combined with Methylphenobarbital.
MidodrineBopindolol may increase the bradycardic activities of Midodrine.
MilnacipranThe serum concentration of Bopindolol can be increased when it is combined with Milnacipran.
MinaprineMinaprine may increase the bradycardic activities of Bopindolol.
MoricizineMoricizine may increase the hypotensive activities of Bopindolol.
Mycophenolate mofetilMycophenolate mofetil may decrease the antihypertensive activities of Bopindolol.
Mycophenolic acidMycophenolic acid may decrease the antihypertensive activities of Bopindolol.
NabumetoneNabumetone may decrease the antihypertensive activities of Bopindolol.
NaftifineNaftifine may decrease the antihypertensive activities of Bopindolol.
NaphazolineNaphazoline may increase the atrioventricular blocking (AV block) activities of Bopindolol.
NaproxenNaproxen may decrease the antihypertensive activities of Bopindolol.
NCX 4016NCX 4016 may decrease the antihypertensive activities of Bopindolol.
NeostigmineNeostigmine may increase the bradycardic activities of Bopindolol.
NepafenacNepafenac may decrease the antihypertensive activities of Bopindolol.
NicotineThe risk or severity of adverse effects can be increased when Bopindolol is combined with Nicotine.
Nicotine bitartrateThe risk or severity of adverse effects can be increased when Bopindolol is combined with Nicotine bitartrate.
NifedipineNifedipine may increase the hypotensive activities of Bopindolol.
Niflumic AcidNiflumic Acid may decrease the antihypertensive activities of Bopindolol.
NimesulideNimesulide may decrease the antihypertensive activities of Bopindolol.
NorepinephrineNorepinephrine may increase the atrioventricular blocking (AV block) activities of Bopindolol.
NorepinephrineBopindolol may decrease the bronchodilatory activities of Norepinephrine.
OlanzapineThe serum concentration of Bopindolol can be increased when it is combined with Olanzapine.
OlodaterolBopindolol may decrease the bronchodilatory activities of Olodaterol.
OlopatadineOlopatadine may decrease the antihypertensive activities of Bopindolol.
OlsalazineOlsalazine may decrease the antihypertensive activities of Bopindolol.
OrciprenalineBopindolol may decrease the bronchodilatory activities of Orciprenaline.
OrgoteinOrgotein may decrease the antihypertensive activities of Bopindolol.
OuabainBopindolol may increase the bradycardic activities of Ouabain.
OxaprozinOxaprozin may decrease the antihypertensive activities of Bopindolol.
OxymetazolineOxymetazoline may increase the atrioventricular blocking (AV block) activities of Bopindolol.
OxyphenbutazoneOxyphenbutazone may decrease the antihypertensive activities of Bopindolol.
PaliperidonePaliperidone may increase the atrioventricular blocking (AV block) activities of Bopindolol.
ParecoxibParecoxib may decrease the antihypertensive activities of Bopindolol.
ParoxetineThe serum concentration of Bopindolol can be increased when it is combined with Paroxetine.
PentobarbitalThe serum concentration of Bopindolol can be decreased when it is combined with Pentobarbital.
PergolidePergolide may increase the atrioventricular blocking (AV block) activities of Bopindolol.
PerphenazinePerphenazine may increase the hypotensive activities of Bopindolol.
PhenobarbitalThe serum concentration of Bopindolol can be decreased when it is combined with Phenobarbital.
PhenylbutazonePhenylbutazone may decrease the antihypertensive activities of Bopindolol.
PhenylpropanolaminePhenylpropanolamine may increase the atrioventricular blocking (AV block) activities of Bopindolol.
PhenylpropanolamineBopindolol may decrease the bronchodilatory activities of Phenylpropanolamine.
PhysostigminePhysostigmine may increase the bradycardic activities of Bopindolol.
PilocarpineThe risk or severity of adverse effects can be increased when Bopindolol is combined with Pilocarpine.
PimecrolimusPimecrolimus may decrease the antihypertensive activities of Bopindolol.
PirbuterolBopindolol may decrease the bronchodilatory activities of Pirbuterol.
PirfenidonePirfenidone may decrease the antihypertensive activities of Bopindolol.
PiroxicamPiroxicam may decrease the antihypertensive activities of Bopindolol.
PrazosinBopindolol may increase the orthostatic hypotensive activities of Prazosin.
PrimaquineThe metabolism of Bopindolol can be decreased when combined with Primaquine.
PrimidoneThe serum concentration of Bopindolol can be decreased when it is combined with Primidone.
ProcaterolBopindolol may decrease the bronchodilatory activities of Procaterol.
ProchlorperazineProchlorperazine may increase the hypotensive activities of Bopindolol.
PromazinePromazine may increase the hypotensive activities of Bopindolol.
PromethazinePromethazine may increase the hypotensive activities of Bopindolol.
PropacetamolPropacetamol may decrease the antihypertensive activities of Bopindolol.
PropafenoneThe serum concentration of Bopindolol can be increased when it is combined with Propafenone.
PseudoephedrinePseudoephedrine may increase the atrioventricular blocking (AV block) activities of Bopindolol.
PTC299PTC299 may decrease the antihypertensive activities of Bopindolol.
PyridostigminePyridostigmine may increase the bradycardic activities of Bopindolol.
RegorafenibRegorafenib may increase the bradycardic activities of Bopindolol.
ReserpineReserpine may increase the hypotensive activities of Bopindolol.
ResveratrolResveratrol may decrease the antihypertensive activities of Bopindolol.
RisperidoneRisperidone may increase the atrioventricular blocking (AV block) activities of Bopindolol.
RitodrineBopindolol may decrease the bronchodilatory activities of Ritodrine.
RivastigmineRivastigmine may increase the bradycardic activities of Bopindolol.
RofecoxibRofecoxib may decrease the antihypertensive activities of Bopindolol.
RopiniroleRopinirole may increase the atrioventricular blocking (AV block) activities of Bopindolol.
SalbutamolBopindolol may decrease the bronchodilatory activities of Salbutamol.
SalicylamideSalicylamide may decrease the antihypertensive activities of Bopindolol.
Salicylic acidSalicylic acid may decrease the antihypertensive activities of Bopindolol.
SalmeterolBopindolol may decrease the bronchodilatory activities of Salmeterol.
SalsalateSalsalate may decrease the antihypertensive activities of Bopindolol.
SecobarbitalThe serum concentration of Bopindolol can be decreased when it is combined with Secobarbital.
SeratrodastSeratrodast may decrease the antihypertensive activities of Bopindolol.
SertralineThe serum concentration of Bopindolol can be increased when it is combined with Sertraline.
SilodosinBopindolol may increase the orthostatic hypotensive activities of Silodosin.
SRT501SRT501 may decrease the antihypertensive activities of Bopindolol.
SulfasalazineSulfasalazine may decrease the antihypertensive activities of Bopindolol.
SulindacSulindac may decrease the antihypertensive activities of Bopindolol.
SuprofenSuprofen may decrease the antihypertensive activities of Bopindolol.
TacrineTacrine may increase the bradycardic activities of Bopindolol.
TamsulosinBopindolol may increase the orthostatic hypotensive activities of Tamsulosin.
TenoxicamTenoxicam may decrease the antihypertensive activities of Bopindolol.
TepoxalinTepoxalin may decrease the antihypertensive activities of Bopindolol.
TerazosinBopindolol may increase the orthostatic hypotensive activities of Terazosin.
TerbutalineBopindolol may decrease the bronchodilatory activities of Terbutaline.
TeriflunomideTeriflunomide may decrease the antihypertensive activities of Bopindolol.
TheophyllineBopindolol may decrease the bronchodilatory activities of Theophylline.
ThiamylalThe serum concentration of Bopindolol can be decreased when it is combined with Thiamylal.
ThiethylperazineThiethylperazine may increase the hypotensive activities of Bopindolol.
ThiopentalThe serum concentration of Bopindolol can be decreased when it is combined with Thiopental.
ThioridazineThioridazine may increase the hypotensive activities of Bopindolol.
Tiaprofenic acidTiaprofenic acid may decrease the antihypertensive activities of Bopindolol.
TizanidineTizanidine may increase the atrioventricular blocking (AV block) activities of Bopindolol.
TolazamideBopindolol may increase the hypoglycemic activities of Tolazamide.
TolbutamideBopindolol may increase the hypoglycemic activities of Tolbutamide.
Tolfenamic AcidTolfenamic Acid may decrease the antihypertensive activities of Bopindolol.
TolmetinTolmetin may decrease the antihypertensive activities of Bopindolol.
TranilastTranilast may decrease the antihypertensive activities of Bopindolol.
TrazodoneThe serum concentration of Bopindolol can be increased when it is combined with Trazodone.
TrichlorfonTrichlorfon may increase the bradycardic activities of Bopindolol.
TrifluoperazineTrifluoperazine may increase the hypotensive activities of Bopindolol.
TriflupromazineTriflupromazine may increase the hypotensive activities of Bopindolol.
TrimazosinBopindolol may increase the orthostatic hypotensive activities of Trimazosin.
Trisalicylate-cholineTrisalicylate-choline may decrease the antihypertensive activities of Bopindolol.
TubocurarineTubocurarine may increase the bradycardic activities of Bopindolol.
ValdecoxibValdecoxib may decrease the antihypertensive activities of Bopindolol.
VareniclineThe risk or severity of adverse effects can be increased when Bopindolol is combined with Varenicline.
VilanterolBopindolol may decrease the bronchodilatory activities of Vilanterol.
VilazodoneThe serum concentration of Bopindolol can be increased when it is combined with Vilazodone.
VortioxetineThe serum concentration of Bopindolol can be increased when it is combined with Vortioxetine.
XylometazolineXylometazoline may increase the atrioventricular blocking (AV block) activities of Bopindolol.
ZaltoprofenZaltoprofen may decrease the antihypertensive activities of Bopindolol.
ZileutonZileuton may decrease the antihypertensive activities of Bopindolol.
ZimelidineThe serum concentration of Bopindolol can be increased when it is combined with Zimelidine.
ZomepiracZomepirac may decrease the antihypertensive activities of Bopindolol.
Food InteractionsNot Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
partial agonist
General Function:
Receptor signaling protein activity
Specific Function:
Beta-adrenergic receptors mediate the catecholamine-induced activation of adenylate cyclase through the action of G proteins. This receptor binds epinephrine and norepinephrine with approximately equal affinity. Mediates Ras activation through G(s)-alpha- and cAMP-mediated signaling.
Gene Name:
ADRB1
Uniprot ID:
P08588
Molecular Weight:
51322.1 Da
References
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
  2. Joseph SS, Lynham JA, Molenaar P, Grace AA, Colledge WH, Kaumann AJ: Intrinsic sympathomimetic activity of (-)-pindolol mediated through a (-)-propranolol-resistant site of the beta1-adrenoceptor in human atrium and recombinant receptors. Naunyn Schmiedebergs Arch Pharmacol. 2003 Dec;368(6):496-503. Epub 2003 Nov 8. [PubMed:14608456 ]
  3. Doggrell SA: Effects of (+/-)- (+)- and (-)-metoprolol, (+/-)- (+)- and (-)-pindolol, (+/-)-mepindolol and (+/-)-bopindolol on the rat left atria and portal vein. Gen Pharmacol. 1991;22(6):1169-77. [PubMed:1687398 ]
  4. Berendsen HH, Broekkamp CL, Van Delft AM: Antagonism of 8-OH-DPAT-induced behaviour in rats. Eur J Pharmacol. 1990 Oct 2;187(1):97-103. [PubMed:2148726 ]
  5. Watkins DJ, Lawrence AJ, Lewis SJ, Jarrott B: Loss of [125I]-pindolol binding to beta-adrenoceptors on rat nodose ganglion after chronic isoprenaline treatment. J Auton Nerv Syst. 1996 Aug 27;60(1-2):12-6. [PubMed:8884690 ]
  6. Brodde OE, Michel MC, Wang XL, Zerkowski HR: Chronic beta-adrenoceptor antagonist treatment modulates human cardiac and vascular beta-adrenoceptor density in a subtype-selective fashion. J Hypertens Suppl. 1988 Dec;6(4):S497-500. [PubMed:2907348 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
partial agonist
General Function:
Protein homodimerization activity
Specific Function:
Beta-adrenergic receptors mediate the catecholamine-induced activation of adenylate cyclase through the action of G proteins. The beta-2-adrenergic receptor binds epinephrine with an approximately 30-fold greater affinity than it does norepinephrine.
Gene Name:
ADRB2
Uniprot ID:
P07550
Molecular Weight:
46458.32 Da
References
  1. Rubenstein LA, Zauhar RJ, Lanzara RG: Molecular dynamics of a biophysical model for beta2-adrenergic and G protein-coupled receptor activation. J Mol Graph Model. 2006 Dec;25(4):396-409. Epub 2006 Mar 30. [PubMed:16574446 ]
  2. Dejgaard A, Liggett SB, Christensen NJ, Cryer PE, Hilsted J: Adrenergic receptors are a fallible index of adrenergic denervation hypersensitivity. Scand J Clin Lab Invest. 1991 Dec;51(8):659-66. [PubMed:1666931 ]
  3. Wheeldon NM, Newnham DM, Fraser GC, McDevitt DG, Lipworth BJ: The effect of pindolol on creatine kinase is not due to beta 2-adrenoceptor partial agonist activity. Br J Clin Pharmacol. 1991 Jun;31(6):723-4. [PubMed:1678274 ]
  4. Doggrell SA: Effects of (+/-)- (+)- and (-)-metoprolol, (+/-)- (+)- and (-)-pindolol, (+/-)-mepindolol and (+/-)-bopindolol on the rat left atria and portal vein. Gen Pharmacol. 1991;22(6):1169-77. [PubMed:1687398 ]
  5. Doggrell SA: Relaxant and beta 2-adrenoceptor blocking activities of (+/- )-, (+)- and (-)-pindolol on the rat isolated aorta. J Pharm Pharmacol. 1990 Jun;42(6):444-6. [PubMed:1979630 ]
  6. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Serotonin receptor activity
Specific Function:
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various drugs and psychoactive substances. Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of down-stream effectors, such as adenylate cyclase. Beta-arrestin family members inhibit signaling via G pro...
Gene Name:
HTR1A
Uniprot ID:
P08908
Molecular Weight:
46106.335 Da
References
  1. Smeraldi E, Benedetti F, Barbini B, Campori E, Colombo C: Sustained antidepressant effect of sleep deprivation combined with pindolol in bipolar depression. A placebo-controlled trial. Neuropsychopharmacology. 1999 Apr;20(4):380-5. [PubMed:10088139 ]
  2. Haddjeri N, de Montigny C, Blier P: Modulation of the firing activity of rat serotonin and noradrenaline neurons by (+/-)pindolol. Biol Psychiatry. 1999 May 1;45(9):1163-9. [PubMed:10331108 ]
  3. Gobert A, Millan MJ: Modulation of dialysate levels of dopamine, noradrenaline, and serotonin (5-HT) in the frontal cortex of freely-moving rats by (-)-pindolol alone and in association with 5-HT reuptake inhibitors: comparative roles of beta-adrenergic, 5-HT1A, and 5-HT1B receptors. Neuropsychopharmacology. 1999 Aug;21(2):268-84. [PubMed:10432475 ]
  4. Andree B, Thorberg SO, Halldin C, Farde L: Pindolol binding to 5-HT1A receptors in the human brain confirmed with positron emission tomography. Psychopharmacology (Berl). 1999 Jun;144(3):303-5. [PubMed:10435400 ]
  5. Fornal CA, Martin FJ, Metzler CW, Jacobs BL: Pindolol suppresses serotonergic neuronal activity and does not block the inhibition of serotonergic neurons produced by 8-hydroxy-2-(di-n-propylamino)tetralin in awake cats. J Pharmacol Exp Ther. 1999 Oct;291(1):229-38. [PubMed:10490909 ]
  6. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Serotonin receptor activity
Specific Function:
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for ergot alkaloid derivatives, various anxiolytic and antidepressant drugs and other psychoactive substances, such as lysergic acid diethylamide (LSD). Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of ...
Gene Name:
HTR1B
Uniprot ID:
P28222
Molecular Weight:
43567.535 Da
References
  1. Dawson LA, Nguyen HQ: The role of 5-HT(1A) and 5-HT(1B/1D) receptors on the modulation of acute fluoxetine-induced changes in extracellular 5-HT: the mechanism of action of (+/-)pindolol. Neuropharmacology. 2000 Apr 3;39(6):1044-52. [PubMed:10727715 ]
  2. Ariani K, Hamblin MW, Tan GL, Stratford CA, Ciaranello RD: G protein dependent alterations in [125I]iodocyanopindolol and +/- cyanopindolol binding at 5-HT1B binding sites in rat brain membranes. Neurochem Res. 1989 Sep;14(9):835-43. [PubMed:2512511 ]
  3. Leonhardt S, Herrick-Davis K, Titeler M: Detection of a novel serotonin receptor subtype (5-HT1E) in human brain: interaction with a GTP-binding protein. J Neurochem. 1989 Aug;53(2):465-71. [PubMed:2664084 ]
  4. Herrick-Davis K, Titeler M, Leonhardt S, Struble R, Price D: Serotonin 5-HT1D receptors in human prefrontal cortex and caudate: interaction with a GTP binding protein. J Neurochem. 1988 Dec;51(6):1906-12. [PubMed:3141589 ]
  5. Terron JA, Lopez-Munoz FJ, Hong E, Villalon CM: 2-(2-Aminoethyl)-quinoline (D-1997): a novel agonist at 5-hydroxytryptamine1-like receptors in the canine basilar artery. Arch Int Pharmacodyn Ther. 1994 Jan-Feb;327(1):56-68. [PubMed:7944828 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Protein homodimerization activity
Specific Function:
Beta-adrenergic receptors mediate the catecholamine-induced activation of adenylate cyclase through the action of G proteins. Beta-3 is involved in the regulation of lipolysis and thermogenesis.
Gene Name:
ADRB3
Uniprot ID:
P13945
Molecular Weight:
43518.615 Da
References
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
Comments
comments powered by Disqus
Drug created on October 20, 2010 15:16 / Updated on August 17, 2016 12:24